Polynovo (ASX:PNV) ROCE %: 4.74% (As of Dec. 2025)

What is Polynovo ROCE %?

Polynovo ASX:PNV -3.70% 76 ROCE % is 4.74% as of Dec. 2025. GuruFocus rates ASX:PNV with a GF Score™ of 76/100 and a GF Value™ of A$3.24 (Significantly Undervalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Polynovo's annualized ROCE % for the quarter that ended in Dec. 2025 was 4.74%.

Polynovo (ASX:PNV) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Polynovo ROCE % Related Terms

Polynovo ROCE % Historical Data

* Premium members only.

The historical data trend for Polynovo's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Polynovo ROCE % Chart

Polynovo Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

ROCE %

Get a 7-Day Free Trial

-14.91

-2.94

-8.86

2.24

8.38

Polynovo Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
ROCE %	Get a 7-Day Free Trial															2.80	1.68	13.87	3.54	4.74

76GF Score

Polynovo Ltd ASX:PNV

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Polynovo ROCE % Calculation

Polynovo's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2025 )		(A: Jun. 2024 )		(A: Jun. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2025 )		(A: Jun. 2024 )		(A: Jun. 2025 )
	=	7.755	/	( ( (108.72 - 23.247)	+	(127.408 - 27.882) )	/ 2 )
	=	7.755	/	( (85.473	+	99.526)	/ 2 )
	=	7.755	/	92.4995
	=	8.38 %

Polynovo's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2025 )		(Q: Jun. 2025 )		(Q: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2025 )		(Q: Jun. 2025 )		(Q: Dec. 2025 )
	=	4.746	/	( ( (127.408 - 27.882)	+	(123.368 - 22.813) )	/ 2 )
	=	4.746	/	( ( 99.526	+	100.555 )	/ 2 )
	=	4.746	/	100.0405
	=	4.74 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 4.74% mean?

Polynovo (ASX:PNV) has a ROCE % of 4.74% as of Dec. 2025.

Is Polynovo's ROCE % too high?

Polynovo's current ROCE % is 4.74%. The Medical Devices & Instruments industry median ROCE % is 2.23. Polynovo's value of 4.74% is 112.6% above this industry median. Overall, Polynovo has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Polynovo's ROCE % compare to ABT and SYK?

Polynovo's ROCE % of 4.74% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Polynovo's value of 4.74% is 112.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Polynovo's current ROCE % of 4.74% is 112.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Polynovo's current ROCE % is 4.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Polynovo stock overvalued right now?

Based on GuruFocus' analysis, Polynovo (ASX:PNV) is currently considered Significantly Undervalued. The stock's GF Value™ is A$3.24, compared to a current price of A$0.91 — trading 71.9% below its estimated fair value. The current ROCE % is 4.74% and 112.6% above the Medical Devices & Instruments industry median of 2.23. Polynovo's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Polynovo (ASX:PNV), the current ROCE % is 4.74% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Polynovo (ASX:PNV) Overvalued in 2026?

Based on GuruFocus' analysis, Polynovo stock appears to be undervalued. The current stock price of A$0.91 is trading 71.9% below its estimated GF Value™ of A$3.24. GuruFocus considers Polynovo to be Significantly Undervalued.

Key valuation signals for ASX:PNV:

ROCE %: 4.74%
GF Value™: A$3.24 vs. price of A$0.91 (71.9% below fair value)
GF Score™: 76/100 with 4 warning signs
Industry Position: 112.6% above the Medical Devices & Instruments median

No single metric tells the full story. See the ASX:PNV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Polynovo Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies ASX:IMR ASX:ARX ASX:EMV ASX:SOM ASX:LDX ASX:COV ASX:CMP ASX:HMD ASX:CSX ASX:EYE ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA

Other Exchanges CALZF:USA MFJ:Germany

Address 320 Lorimer Street, Unit 2, Port Melbourne, VIC, AUS, 3207

Website https://www.polynovo.com

Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.

76GF Score

Get the complete analysis for ASX:PNV

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.91

Price

A$3.24

GF Value

View ASX:PNV Analysis

See ROCE % data for all stocks →